NetworkNewsBreaks – Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) Releases Pricing of Underwritten Public Offering to Total Estimated $15M
Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company developing innovative targeted biologic drugs, is reporting the pricing of its underwritten public offering; the offering consists of 13,888,888 shares of common stock or common stock equivalents, including prefunded warrants to purchase shares of common stock in lieu of shares of common stock and investor warrants to purchase up to an aggregate of 27,777,776 shares of common stock. According to the announcement, the common stock shares (or prefunded warrants in lieu thereof) are being combined and sold with one investor warrant enabling the purchase of two shares of common stock at a combined…







